Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286948 | 0.89 | KMT2A (0.50) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 | |
| SCHEMBL4279961 | 0.86 | KMT2A (0.51) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 | |
| SCHEMBL4279804 | 0.84 | SMN1; SMN2 (0.55) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 | |
| SCHEMBL4293142 | 0.84 | ALDH1A1 (0.51) | KMT2ASMN1; SMN2ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4281447 | 0.83 | TSHR (0.51) | KMT2ASMN1; SMN2MEN1ALDH1A1EPHX2 | |
| SCHEMBL4281575 | 0.83 | RAB9A (0.48) | KMT2ASMN1; SMN2MEN1ALDH1A1EPHX2 | |
| SCHEMBL4287145 | 0.82 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 | |
| SCHEMBL4293196 | 0.82 | KMT2A (0.44) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 | |
| SCHEMBL4287623 | 0.82 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 | |
| SCHEMBL4279912 | 0.82 | KMT2A (0.51) | KMT2ASMN1; SMN2MEN1ALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | KMT2A 871/4885SMN1; SMN2 4064/4885MEN1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.